NL-OMON33076
Completed
Not Applicable
Prospective validation of a predictive model for pathologic complete response after chemoradiotherapy in rectal cancer: A prognostic study - validation of a predictive model after complete response in rectal cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- cancer of the rectum/rectumcancer
- Sponsor
- MAASTRO clinic
- Enrollment
- 60
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histological proven rectal cancer
- •UICC stage I\-III
- •Only primary tumors; no recurrences
- •Willing and able to comply with the study prescriptions
- •18 years or older
- •Have given written informed consent before patient registration
- •No previous radiotherapy to the pelvis
- •Only patients treated with concurrent chemoradiation
Exclusion Criteria
- •Not adenocarcinoma histology
- •History of prior pelvis radiotherapy
- •No contra\-indication for PET\-CT ( claustrofobia/allergy)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Assessment of a predictive response model for romiplostim in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trialPatients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopeniaMedDRA version: 18.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-004328-12-FRGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH90
Active, not recruiting
Phase 1
Assessment of a predictive response model for romiplostim in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trialPatients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopeniaMedDRA version: 20.0Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2013-004328-12-DEGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH75
Completed
Not Applicable
A prospective cohort validation study of predictive score for in-hospital mortality of elderly patients with endogenous diseases transferred by ambulanceInpatients transported by ambulanceJPRN-UMIN000046346Saga University Hospital325
Completed
Not Applicable
Prediction of Risks in Early onset Pre-eclampsia (PREP)Early onset pre-eclampsiaPregnancy and ChildbirthPre-eclampsiaISRCTN40384046Queen Mary University of London (UK)500
Completed
Not Applicable
Prospective study of evaluation to the predictive biomarker of Nivolumab by tumor tissue specimen and neighboring bronchoaveolar lavage fluid (BALF) and BloodJPRN-UMIN000023822Respiratory Medicine, Allergy and Rheumatic Diseases Osaka University Graduate School of Medicine20